MedTrace Logo

Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety

NCT00352469 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-12-08

No results posted yet for this study

Summary

Alcohol use disorders (AUDs) are a major problem facing our society. Their treatment is complex, and involves multiple behavioral and pharmacotherapy interventions. There are 3 approved medications for AUDs, but their efficacy for AUDs that co-exist with anxiety disorders is unknown. This study explores the effects of the medication, sustained-release quetiapine fumarate (Seroquel SR) for the treatment of alcohol dependence and co-morbid anxiety. Primary outcome measure is the amount of alcohol used. Secondary outcome measures include craving for alcohol, length of sobriety from drinking and level of anxiety with Seroquel SR.

Conditions

  • Alcoholism
  • Anxiety Disorders
  • Generalized Anxiety Disorder
  • Post-Traumatic Stress Disorder
  • Panic Disorder
  • Obsessive-Compulsive Disorder

Interventions

DRUG

Seroquel XR

Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Creighton University

    lead OTHER

Principal Investigators

  • Pirzada Sattar, MD · Creighton University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352469 on ClinicalTrials.gov